CCCC C4 Therapeutics
- 6.010
- -0.100-1.64%
C4 Therapeutics News
Analysts Offer Insights on Healthcare Companies: C4 Therapeutics (CCCC), ACADIA Pharmaceuticals (ACAD) and Disc Medicine (IRON)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on C4 Therapeutics (CCCC), ACADIA Pharmaceuticals (ACAD) and Disc Medicine (IRON).
C4 Therapeutics Inc (CCCC) Q1 2024 Earnings: Navigating Challenges With Strategic Collaborations
On May 8, 2024, C4 Therapeutics Inc (NASDAQ:CCCC) released its 8-K filing, detailing the financial results for the first quarter ended March 31, 2024.
C4 Therapeutics Price Target Raised to $8.00/Share From $7.00 by Wells Fargo
C4 Therapeutics Price Target Raised to $8.00/Share From $7.00 by Wells Fargo
C4 Therapeutics Is Maintained at Buy by Stifel
C4 Therapeutics Is Maintained at Buy by Stifel
Stifel Maintains Buy on C4 Therapeutics, Raises Price Target to $14
Stifel analyst Bradley Canino maintains C4 Therapeutics with a Buy and raises the price target from $13 to $14.
C4 Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 113.41% Stifel $13 → $14 Maintains Buy 02/26/2024 21.95% Morgan Stanley $1 → $8 Maintains Equal
C4 Therapeutics: Hold Rating Maintained Amidst Encouraging Drug Progress and Stable Financials
C4 Therapeutics Shares Decline as Q1 Revenue Misses Estimates
C4 Therapeutics (CCCC) shares were down 5% in recent Wednesday trading after the company reported its Q1 earnings. The company reported a Q1 diluted loss of $0.41 per share, narrowing from a per-share
C4 Therapeutics' Cash, Cash Equivalents and Marketable Securities Total $299.2M As Of March 31, 2024; Expected To Provide Runway Into 2027
C4 Therapeutics' Cash, Cash Equivalents and Marketable Securities Total $299.2M As Of March 31, 2024; Expected To Provide Runway Into 2027
C4 Therapeutics | 10-Q: Quarterly report
C4 Therapeutics 1Q Loss $28.4M >CCCC
C4 Therapeutics 1Q Loss $28.4M >CCCC
C4 Therapeutics 1Q Loss/Shr 41c >CCCC
C4 Therapeutics 1Q Loss/Shr 41c >CCCC
Press Release: C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights Successfully Delivered First Development Candidate to Biogen; $8 Million Payment Earned Established a Stra
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Successfully Delivered First Development Candidate to Biogen; $8 Million Payment EarnedEstablished a Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Focused on Two Crit
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WATERTOWN, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation scienc
C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum
WATERTOWN, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation scienc
C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024
WATERTOWN, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation scienc
Here's Why Meridian Small Cap Growth Fund Trimmed C4 Therapeutics (CCCC)
C4 Therapeutics Initiates Stock Option Repricing for Retention
C4 Therapeutics (CCCC) has shared an update.
Over $700 million! Merck joins hands with C4T (CCCC.US) to develop anti-cancer proteolytic therapy
On March 4, C4 Therapeutics (CCCC.US) announced a licensing and cooperation agreement with Merck of Germany
Analysis
Price Target
No Data
